摘要
蛋白酶体激活因子(PA28γ)又称Ki抗原、REGγ或PSME3,最早在1例系统性红斑狼疮患者血清中发现,与PA28α和PA28β同属于11S蛋白酶体激活因子家族。在氨基酸序列上,PA28γ与PA28α和PA28β有25%的同源性。其七亚基同聚体是20S蛋白酶体激活因子,主要存在于细胞核中并参与非泛素化和ATP依赖或非依赖的蛋白质降解过程。越来越多的研究报道了PA28γ在人类免疫相关疾病中发挥的作用。本文综述了近年来PA28γ作为蛋白酶体激活因子的功能及其在免疫相关疾病,包括癌症、炎症和病毒感染相关疾病及其他疾病中的作用,从而揭示PA28γ在免疫相关疾病发生发展中的作用及其作为免疫治疗诊治靶点的潜在可能性。
Proteasome activator PA28γ,also known as Ki antigen,REGγor PSME3,is first found as Ki antigen in the serum of a patient with systemic lupus erythematosus,which belongs to 11S proteasome activator family together with PA28αand PA28β.In the amino acid sequence,PA28γhas 25%homology with PA28αand PA28βand its seven-subunit homomer is a 20S proteasome acti-vator,which mainly exists in the nucleus and participates in ubiquitin and ATP-dependent or independent protein degradation.More and more studies have reported the role of PA28γin human immune-related diseases.This article reviews the function of PA28γas a proteasome activator and its role in immune-related diseases including cancer,inflammation and virus infection-related diseases and other diseases in recent years,so as to reveal the role of PA28γin the occurrence and development of immune-related diseases and its potential as a target for immunotherapy.
作者
苏崇莹
牛嘉璐
古浚杰
李敬
SU Chongying;NIU Jialu;GU Junjie;LI Jing(National Key Laboratory of Oral Diseases Prevention and Treatment,Sichuan University,Chengdu 610041,China;Clinical Medicine Center,West China School of Stomatology,Sichuan University,Innovation Unit of Oral Mucosal Cancer and Prevention,Chinese Academy of Medical Sciences,Chengdu 610041,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2024年第1期192-201,共10页
Chinese Journal of Immunology
基金
国家自然科学基金(82072999,81672675)
中国医学科学院“口腔黏膜癌变与防治”创新单元项目(2019-12M-5-004)。
关键词
PA28γ
炎症
肿瘤
病毒感染
治疗靶点
PA28γ
Inflammation
Tumor
Viral infection
Therapeutic target
